Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Equity-to-Asset 0.48
NYSE:JNJ's Equity-to-Asset is ranked lower than
70% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:JNJ: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:JNJ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.54 Max: 0.67
Current: 0.48
0.44
0.67
Debt-to-Equity 0.48
NYSE:JNJ's Debt-to-Equity is ranked lower than
63% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. NYSE:JNJ: 0.48 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:JNJ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06  Med: 0.26 Max: 0.5
Current: 0.48
0.06
0.5
Debt-to-EBITDA 1.57
NYSE:JNJ's Debt-to-EBITDA is ranked higher than
54% of the 511 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. NYSE:JNJ: 1.57 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:JNJ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.58  Med: 0.84 Max: 1.57
Current: 1.57
0.58
1.57
Interest Coverage 22.04
NYSE:JNJ's Interest Coverage is ranked lower than
63% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 127.83 vs. NYSE:JNJ: 22.04 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 22.04  Med: 36.54 Max: 46.15
Current: 22.04
22.04
46.15
Piotroski F-Score: 4
Altman Z-Score: 4.65
Beneish M-Score: -2.40
WACC vs ROIC
5.86%
0.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 24.48
NYSE:JNJ's Operating Margin % is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.71 vs. NYSE:JNJ: 24.48 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:JNJ' s Operating Margin % Range Over the Past 10 Years
Min: 22.36  Med: 25.94 Max: 29.44
Current: 24.48
22.36
29.44
Net Margin % 1.70
NYSE:JNJ's Net Margin % is ranked lower than
65% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. NYSE:JNJ: 1.70 )
Ranked among companies with meaningful Net Margin % only.
NYSE:JNJ' s Net Margin % Range Over the Past 10 Years
Min: 1.7  Med: 20.07 Max: 23.01
Current: 1.7
1.7
23.01
ROE % 1.81
NYSE:JNJ's ROE % is ranked lower than
64% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. NYSE:JNJ: 1.81 )
Ranked among companies with meaningful ROE % only.
NYSE:JNJ' s ROE % Range Over the Past 10 Years
Min: 1.81  Med: 23.04 Max: 30.17
Current: 1.81
1.81
30.17
ROA % 0.88
NYSE:JNJ's ROA % is ranked lower than
63% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. NYSE:JNJ: 0.88 )
Ranked among companies with meaningful ROA % only.
NYSE:JNJ' s ROA % Range Over the Past 10 Years
Min: 0.88  Med: 12.23 Max: 15.61
Current: 0.88
0.88
15.61
ROC (Joel Greenblatt) % 96.47
NYSE:JNJ's ROC (Joel Greenblatt) % is ranked higher than
95% of the 850 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.46 vs. NYSE:JNJ: 96.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:JNJ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 119.25
Current: 96.47
65.66
119.25
3-Year Revenue Growth Rate 1.30
NYSE:JNJ's 3-Year Revenue Growth Rate is ranked lower than
66% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NYSE:JNJ: 1.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:JNJ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 9.05 Max: 14.8
Current: 1.3
1.3
14.8
3-Year EBITDA Growth Rate 7.70
NYSE:JNJ's 3-Year EBITDA Growth Rate is ranked lower than
52% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. NYSE:JNJ: 7.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:JNJ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.6  Med: 11.4 Max: 24.1
Current: 7.7
-6.6
24.1
3-Year EPS without NRI Growth Rate 7.20
NYSE:JNJ's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 650 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. NYSE:JNJ: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:JNJ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 12.45 Max: 34.2
Current: 7.2
-8.6
34.2
GuruFocus has detected 5 Warning Signs with Johnson & Johnson NYSE:JNJ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:JNJ's 30-Y Financials

Financials (Next Earnings Date: 2018-04-18)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

JNJ Guru Trades in Q1 2017

Jim Simons 7,102,700 sh (+107.49%)
Paul Tudor Jones 11,807 sh (+103.57%)
Barrow, Hanley, Mewhinney & Strauss 12,700,845 sh (+6.95%)
Mairs and Power 2,227,380 sh (+3.91%)
T Rowe Price Equity Income Fund 3,500,000 sh (+3.86%)
John Rogers 892,116 sh (+2.50%)
John Buckingham 63,690 sh (+1.55%)
Ken Fisher 11,093,898 sh (+1.25%)
Mario Gabelli 260,455 sh (+1.11%)
Charles Brandes 132,387 sh (+0.79%)
Warren Buffett 327,100 sh (unchged)
Robert Olstein 29,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Prem Watsa 151,250 sh (unchged)
Yacktman Fund 3,200,000 sh (unchged)
Richard Snow 3,215 sh (unchged)
David Rolfe 5,250 sh (unchged)
David Carlson 460,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Sarah Ketterer Sold Out
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Jeff Auxier 103,426 sh (-0.62%)
Tweedy Browne 2,368,267 sh (-0.77%)
Diamond Hill Capital 2,308 sh (-0.82%)
Donald Yacktman 5,919,270 sh (-1.93%)
Dodge & Cox 33,374 sh (-2.37%)
First Eagle Investment 26,921 sh (-3.96%)
Yacktman Focused Fund 1,700,000 sh (-5.56%)
Jeremy Grantham 4,919,730 sh (-6.39%)
Richard Pzena 914,439 sh (-8.46%)
Murray Stahl 24,319 sh (-9.61%)
Lee Ainslie 23,120 sh (-18.96%)
Ruane Cunniff 4,240 sh (-19.05%)
Manning & Napier Advisors, Inc 1,933,205 sh (-34.31%)
Joel Greenblatt 291,296 sh (-38.77%)
Pioneer Investments 2,210,407 sh (-54.24%)
PRIMECAP Management 949,075 sh (-56.29%)
Michael Price 5,000 sh (-75.00%)
Eaton Vance Worldwide Health Sciences Fund 347,253 sh (-22.99%)
» More
Q2 2017

JNJ Guru Trades in Q2 2017

Steven Cohen 669,064 sh (New)
Lee Ainslie 30,100 sh (+30.19%)
David Rolfe 5,750 sh (+9.52%)
John Rogers 950,374 sh (+6.53%)
Ken Fisher 11,499,415 sh (+3.66%)
John Buckingham 65,803 sh (+3.32%)
Pioneer Investments 2,269,192 sh (+2.66%)
Jeremy Grantham 5,049,909 sh (+2.65%)
Tweedy Browne Global Value 865,835 sh (unchged)
Tom Gayner 610,800 sh (unchged)
David Carlson 460,000 sh (unchged)
First Eagle Investment 26,921 sh (unchged)
Prem Watsa 151,250 sh (unchged)
Richard Snow 3,215 sh (unchged)
Michael Price 5,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 347,253 sh (unchged)
Robert Olstein Sold Out
Ruane Cunniff Sold Out
Jeff Auxier 103,401 sh (-0.02%)
Mairs and Power 2,225,499 sh (-0.08%)
T Rowe Price Equity Income Fund 3,495,600 sh (-0.13%)
Murray Stahl 24,206 sh (-0.46%)
Dodge & Cox 33,174 sh (-0.60%)
PRIMECAP Management 941,975 sh (-0.75%)
Mario Gabelli 256,285 sh (-1.60%)
Barrow, Hanley, Mewhinney & Strauss 12,372,873 sh (-2.58%)
Tweedy Browne 2,299,019 sh (-2.92%)
Yacktman Fund 3,100,000 sh (-3.13%)
Donald Yacktman 5,675,362 sh (-4.12%)
Manning & Napier Advisors, Inc 1,832,479 sh (-5.21%)
Diamond Hill Capital 2,184 sh (-5.37%)
Yacktman Focused Fund 1,600,000 sh (-5.88%)
Charles Brandes 122,242 sh (-7.66%)
Jim Simons 6,132,200 sh (-13.66%)
Richard Pzena 737,844 sh (-19.31%)
Paul Tudor Jones 3,371 sh (-71.45%)
Joel Greenblatt 24,933 sh (-91.44%)
» More
Q3 2017

JNJ Guru Trades in Q3 2017

Louis Moore Bacon 20,000 sh (New)
Caxton Associates 5,400 sh (New)
Paul Tudor Jones 38,969 sh (+1056.01%)
Joel Greenblatt 80,883 sh (+224.40%)
Lee Ainslie 39,900 sh (+32.56%)
John Rogers 989,289 sh (+4.09%)
Steven Cohen 689,342 sh (+3.03%)
Ken Fisher 11,797,674 sh (+2.59%)
Murray Stahl 24,618 sh (+1.70%)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Focused Fund 1,600,000 sh (unchged)
Yacktman Fund 3,100,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
David Carlson 460,000 sh (unchged)
First Eagle Investment 26,921 sh (unchged)
Richard Snow 3,215 sh (unchged)
Prem Watsa 151,250 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Rolfe 5,750 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 347,253 sh (unchged)
Richard Pzena Sold Out
Michael Price Sold Out
Tweedy Browne 2,292,554 sh (-0.28%)
Donald Yacktman 5,653,623 sh (-0.38%)
Jeff Auxier 102,851 sh (-0.53%)
Mairs and Power 2,209,403 sh (-0.72%)
John Buckingham 64,847 sh (-1.45%)
PRIMECAP Management 924,225 sh (-1.88%)
Pioneer Investments 2,223,833 sh (-2.00%)
Manning & Napier Advisors, Inc 1,778,271 sh (-2.96%)
Mario Gabelli 247,675 sh (-3.36%)
T Rowe Price Equity Income Fund 3,230,000 sh (-7.60%)
Dodge & Cox 30,514 sh (-8.02%)
Jeremy Grantham 4,564,838 sh (-9.61%)
Barrow, Hanley, Mewhinney & Strauss 10,607,089 sh (-14.27%)
Diamond Hill Capital 1,733 sh (-20.65%)
Jim Simons 4,306,200 sh (-29.78%)
Charles Brandes 58,510 sh (-52.14%)
» More
Q4 2017

JNJ Guru Trades in Q4 2017

First Pacific Advisors 9,700 sh (New)
Tom Russo 1,315 sh (New)
Joel Greenblatt 239,967 sh (+196.68%)
Pioneer Investments 4,719,253 sh (+112.21%)
Caxton Associates 11,177 sh (+106.98%)
Lee Ainslie 67,520 sh (+69.22%)
Diamond Hill Capital 1,909 sh (+10.16%)
Ken Fisher 12,127,379 sh (+2.79%)
John Rogers 1,012,823 sh (+2.38%)
Tweedy Browne Global Value 865,835 sh (unchged)
David Carlson 460,000 sh (unchged)
First Eagle Investment 26,921 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Richard Snow 3,215 sh (unchged)
Prem Watsa 151,250 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 347,253 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 921,323 sh (-0.31%)
Murray Stahl 24,518 sh (-0.41%)
Mairs and Power 2,191,819 sh (-0.80%)
Dodge & Cox 30,240 sh (-0.90%)
Tweedy Browne 2,248,251 sh (-1.93%)
Jeff Auxier 100,455 sh (-2.33%)
John Buckingham 62,884 sh (-3.03%)
David Rolfe 5,550 sh (-3.48%)
T Rowe Price Equity Income Fund 3,100,000 sh (-4.02%)
Jeremy Grantham 4,319,219 sh (-5.38%)
Barrow, Hanley, Mewhinney & Strauss 10,028,494 sh (-5.45%)
Charles Brandes 55,046 sh (-5.92%)
Yacktman Fund 2,900,000 sh (-6.45%)
Donald Yacktman 5,186,544 sh (-8.26%)
Yacktman Focused Fund 1,450,000 sh (-9.38%)
Mario Gabelli 207,376 sh (-16.27%)
Jim Simons 3,469,800 sh (-19.42%)
Steven Cohen 46,900 sh (-93.20%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-12-31 Add 2.79%0.06%$131.22 - $143.62 $ 133.15-4%12,127,379
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -5.45%0.11%$131.22 - $143.62 $ 133.15-4%10,028,494
Donald Yacktman 2017-12-31 Reduce -8.26%0.59%$131.22 - $143.62 $ 133.15-4%5,186,544
T Rowe Price Equity Income Fund 2017-12-31 Reduce -4.02%0.08%$131.22 - $143.62 $ 133.15-4%3,100,000
Yacktman Fund 2017-12-31 Reduce -6.45%0.41%$131.22 - $143.62 $ 133.15-4%2,900,000
Tweedy Browne 2017-12-31 Reduce -1.93%0.16%$131.22 - $143.62 $ 133.15-4%2,248,251
Yacktman Focused Fund 2017-12-31 Reduce -9.38%0.61%$131.22 - $143.62 $ 133.15-4%1,450,000
John Rogers 2017-12-31 Add 2.38%0.04%$131.22 - $143.62 $ 133.15-4%1,012,823
Joel Greenblatt 2017-12-31 Add 196.68%0.32%$131.22 - $143.62 $ 133.15-4%239,967
Mario Gabelli 2017-12-31 Reduce -16.27%0.03%$131.22 - $143.62 $ 133.15-4%207,376
Charles Brandes 2017-12-31 Reduce -5.92%0.01%$131.22 - $143.62 $ 133.15-4%55,046
Dodge & Cox 2017-12-31 Reduce -0.90%$131.22 - $143.62 $ 133.15-4%30,240
Ken Fisher 2017-09-30 Add 2.59%0.06%$129.47 - $136.57 $ 133.150%11,797,674
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -14.27%0.36%$129.47 - $136.57 $ 133.150%10,607,089
Donald Yacktman 2017-09-30 Reduce -0.38%0.03%$129.47 - $136.57 $ 133.150%5,653,623
T Rowe Price Equity Income Fund 2017-09-30 Reduce -7.60%0.16%$129.47 - $136.57 $ 133.150%3,230,000
Tweedy Browne 2017-09-30 Reduce -0.28%0.03%$129.47 - $136.57 $ 133.150%2,292,554
John Rogers 2017-09-30 Add 4.09%0.06%$129.47 - $136.57 $ 133.150%989,289
Mario Gabelli 2017-09-30 Reduce -3.36%0.01%$129.47 - $136.57 $ 133.150%247,675
Joel Greenblatt 2017-09-30 Add 224.40%0.1%$129.47 - $136.57 $ 133.150%80,883
Charles Brandes 2017-09-30 Reduce -52.14%0.14%$129.47 - $136.57 $ 133.150%58,510
Dodge & Cox 2017-09-30 Reduce -8.02%$129.47 - $136.57 $ 133.150%30,514
Michael Price 2017-09-30 Sold Out 0.09%$129.47 - $136.57 $ 133.150%0
Richard Pzena 2017-09-30 Sold Out 0.53%$129.47 - $136.57 $ 133.150%0
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -2.58%0.06%$121.37 - $136.43 $ 133.154%12,372,873
Ken Fisher 2017-06-30 Add 3.66%0.09%$121.37 - $136.43 $ 133.154%11,499,415
Donald Yacktman 2017-06-30 Reduce -4.12%0.28%$121.37 - $136.43 $ 133.154%5,675,362
T Rowe Price Equity Income Fund 2017-06-30 Reduce -0.13%$121.37 - $136.43 $ 133.154%3,495,600
Yacktman Fund 2017-06-30 Reduce -3.13%0.19%$121.37 - $136.43 $ 133.154%3,100,000
Tweedy Browne 2017-06-30 Reduce -2.92%0.25%$121.37 - $136.43 $ 133.154%2,299,019
Yacktman Focused Fund 2017-06-30 Reduce -5.88%0.36%$121.37 - $136.43 $ 133.154%1,600,000
John Rogers 2017-06-30 Add 6.53%0.09%$121.37 - $136.43 $ 133.154%950,374
Richard Pzena 2017-06-30 Reduce -19.31%0.12%$121.37 - $136.43 $ 133.154%737,844
Mario Gabelli 2017-06-30 Reduce -1.60%$121.37 - $136.43 $ 133.154%256,285
Charles Brandes 2017-06-30 Reduce -7.66%0.02%$121.37 - $136.43 $ 133.154%122,242
Dodge & Cox 2017-06-30 Reduce -0.60%$121.37 - $136.43 $ 133.154%33,174
Joel Greenblatt 2017-06-30 Reduce -91.44%0.42%$121.37 - $136.43 $ 133.154%24,933
Ruane Cunniff 2017-06-30 Sold Out $121.37 - $136.43 $ 133.154%0
Robert Olstein 2017-06-30 Sold Out 0.46%$121.37 - $136.43 $ 133.154%0
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Add 6.95%0.15%$111.76 - $128.96 $ 133.1511%12,700,845
Ken Fisher 2017-03-31 Add 1.25%0.03%$111.76 - $128.96 $ 133.1511%11,093,898
Donald Yacktman 2017-03-31 Reduce -1.93%0.12%$111.76 - $128.96 $ 133.1511%5,919,270
T Rowe Price Equity Income Fund 2017-03-31 Add 3.86%0.07%$111.76 - $128.96 $ 133.1511%3,500,000
Tweedy Browne 2017-03-31 Reduce -0.77%0.07%$111.76 - $128.96 $ 133.1511%2,368,267
Yacktman Focused Fund 2017-03-31 Reduce -5.56%0.33%$111.76 - $128.96 $ 133.1511%1,700,000
Richard Pzena 2017-03-31 Reduce -8.46%0.06%$111.76 - $128.96 $ 133.1511%914,439
John Rogers 2017-03-31 Add 2.50%0.03%$111.76 - $128.96 $ 133.1511%892,116
Joel Greenblatt 2017-03-31 Reduce -38.77%0.28%$111.76 - $128.96 $ 133.1511%291,296
Mario Gabelli 2017-03-31 Add 1.11%$111.76 - $128.96 $ 133.1511%260,455
Charles Brandes 2017-03-31 Add 0.79%$111.76 - $128.96 $ 133.1511%132,387
Dodge & Cox 2017-03-31 Reduce -2.37%$111.76 - $128.96 $ 133.1511%33,374
First Eagle Investment 2017-03-31 Reduce -3.96%$111.76 - $128.96 $ 133.1511%26,921
Michael Price 2017-03-31 Reduce -75.00%0.21%$111.76 - $128.96 $ 133.1511%5,000
Ruane Cunniff 2017-03-31 Reduce -19.05%$111.76 - $128.96 $ 133.1511%4,240
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:PFE, XSWX:NOVN, XSWX:ROG, NYSE:ABBV, NYSE:MRK, XPAR:SAN, NYSE:BMY, XTER:BAYA, NYSE:LLY, LSE:GSK, LSE:AZN, TSE:4519, TSE:4503, TSE:4578, TSE:4568, HKSE:01093, TSE:4528, TSE:4151, MIL:REC, BOM:500087 » details
Traded in other countries:JNJ.Argentina, JNJ.Austria, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Headquarter Location:USA
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. Close to half of total revenue is generated within the United States.

Guru Investment Theses on Johnson & Johnson

Jeff Auxier Comments on Johnson & Johnson - Feb 06, 2018

Johnson & Johnson (NYSE:JNJ) saw a 10.3% growth in net sales as their Pharmaceutical segment–which represents 49% of overall sales–jumped 15% in the quarter. This has been due in part to the consistently growing sales of their lymphoma treatment, Imbruvica, increasing 46.7% year over year as additional implications continue to be approved by the FDA.







From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Johnson & Johnson - Aug 03, 2017

AAA rated Johnson & Johnson (NYSE:JNJ) is the world’s largest medical conglomerate. Johnson & Johnson just completed the acquisition of Actelion which gives them a sixth therapeutic area to address potential patients with pulmonary arterial hypertension. Johnson & Johnson expects the acquisition of Actelion to add $1.3 billion in sales for 2017.




From Jeff Auxier (Trades, Portfolio)'s second-quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Ariel Funds Comments on Johnson & Johnson - Sep 28, 2016

Medical giant Johnson & Johnson (NYSE:JNJ) rallied +12.66%, due to a strong earnings report. In April the company beat analysts’ estimates and also raised guidance for the year. Earnings were driven by strong sales of drugs like Stelara and Xarelto. At this point pharmaceuticals are the company’s largest business division—ahead of powerhouses such as medical devices and consumer health products. We think the trajectory of the business continues to point upward.



From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Yacktman Funds Comments on Johnson & Johnson - Aug 05, 2016

JNJ (NYSE:JNJ) performed well in the second quarter after delivering solid results. Few companies have the financial strength and product diversity of JNJ, which is why it is one of only two companies in the United States (Microsoft is the other) that commands a triple-A credit rating. We think JNJ can deliver solid growth and strong free cash flow over time.



From Yacktman Focused Fund (Trades, Portfolio) second quarter 2016 commentary.


Check out Donald Yacktman,Yacktman Focused Fund latest stock trades

Top Ranked Articles about Johnson & Johnson

Charlie Tian: Standing on the Shoulders of the Gurus His book, 'Invest Like a Guru,' provides ideas and insights and, fittingly, starts with the gurus
Johnson & Johnson Consumer Presents New Scientific Research At 2018 American Academy of Dermatology Annual Meeting
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Johnson & Johnson (NYSE: JNJ) To Contact Brower Piven Before The Lead Plaintiff Deadline
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline: April 9, 2018
Johnson & Johnson to Participate in the 2018 CAGNY Conference
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Johnson & Johnson (JNJ)
Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Johnson & Johnson – JNJ
Johnson & Johnson to Participate in RBC Capital Markets 2018 Global Healthcare Conference
Jeff Auxier Comments on Johnson & Johnson Guru stock highlight
Johnson & Johnson (NYSE:JNJ) saw a 10.3% growth in net sales as their Pharmaceutical segment–which represents 49% of overall sales–jumped 15% in the quarter. This has been due in part to the consistently growing sales of their lymphoma treatment, Imbruvica, increasing 46.7% year over year as additional implications continue to be approved by the FDA.
Read more...

Ratios

vs
industry
vs
history
PE Ratio 341.41
JNJ's PE Ratio is ranked lower than
97% of the 573 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.21 vs. JNJ: 341.41 )
Ranked among companies with meaningful PE Ratio only.
JNJ' s PE Ratio Range Over the Past 10 Years
Min: 10.5  Med: 18 Max: 341.41
Current: 341.41
10.5
341.41
Forward PE Ratio 16.47
JNJ's Forward PE Ratio is ranked lower than
53% of the 73 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.67 vs. JNJ: 16.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 341.41
JNJ's PE Ratio without NRI is ranked lower than
98% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.28 vs. JNJ: 341.41 )
Ranked among companies with meaningful PE Ratio without NRI only.
JNJ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.5  Med: 18 Max: 341.41
Current: 341.41
10.5
341.41
Price-to-Owner-Earnings 19.31
JNJ's Price-to-Owner-Earnings is ranked higher than
76% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.28 vs. JNJ: 19.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JNJ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.19  Med: 17.46 Max: 25.26
Current: 19.31
10.19
25.26
PB Ratio 4.83
JNJ's PB Ratio is ranked lower than
69% of the 825 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. JNJ: 4.83 )
Ranked among companies with meaningful PB Ratio only.
JNJ' s PB Ratio Range Over the Past 10 Years
Min: 2.68  Med: 3.72 Max: 5.35
Current: 4.83
2.68
5.35
PS Ratio 4.92
JNJ's PS Ratio is ranked lower than
64% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. JNJ: 4.92 )
Ranked among companies with meaningful PS Ratio only.
JNJ' s PS Ratio Range Over the Past 10 Years
Min: 2.16  Med: 3.22 Max: 5.45
Current: 4.92
2.16
5.45
Price-to-Free-Cash-Flow 19.82
JNJ's Price-to-Free-Cash-Flow is ranked higher than
64% of the 217 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.63 vs. JNJ: 19.82 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JNJ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.29  Med: 16.52 Max: 24.34
Current: 19.82
10.29
24.34
Price-to-Operating-Cash-Flow 16.95
JNJ's Price-to-Operating-Cash-Flow is ranked higher than
55% of the 294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.74 vs. JNJ: 16.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JNJ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.99  Med: 13.2 Max: 19.52
Current: 16.95
8.99
19.52
EV-to-EBIT 20.19
JNJ's EV-to-EBIT is ranked lower than
51% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.21 vs. JNJ: 20.19 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 13.2 Max: 20.8
Current: 20.19
7.8
20.8
EV-to-EBITDA 16.79
JNJ's EV-to-EBITDA is ranked higher than
50% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.57 vs. JNJ: 16.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 11.1 Max: 16.8
Current: 16.79
6.7
16.8
EV-to-Revenue 4.93
JNJ's EV-to-Revenue is ranked lower than
63% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. JNJ: 4.93 )
Ranked among companies with meaningful EV-to-Revenue only.
JNJ' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.2 Max: 5.7
Current: 4.93
2.1
5.7
PEG Ratio 2.54
JNJ's PEG Ratio is ranked lower than
62% of the 313 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. JNJ: 2.54 )
Ranked among companies with meaningful PEG Ratio only.
JNJ' s PEG Ratio Range Over the Past 10 Years
Min: 1.19  Med: 2.07 Max: 27.59
Current: 2.54
1.19
27.59
Shiller PE Ratio 25.73
JNJ's Shiller PE Ratio is ranked higher than
69% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.75 vs. JNJ: 25.73 )
Ranked among companies with meaningful Shiller PE Ratio only.
JNJ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.52  Med: 21.34 Max: 28.5
Current: 25.73
15.52
28.5
Current Ratio 1.32
JNJ's Current Ratio is ranked lower than
78% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.46 vs. JNJ: 1.32 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.95 Max: 3.08
Current: 1.32
1.2
3.08
Quick Ratio 1.02
JNJ's Quick Ratio is ranked lower than
75% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. JNJ: 1.02 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.49 Max: 2.68
Current: 1.02
0.94
2.68
Days Inventory 128.79
JNJ's Days Inventory is ranked lower than
56% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.37 vs. JNJ: 128.79 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 110.33 Max: 137.6
Current: 128.79
100.19
137.6
Days Sales Outstanding 62.81
JNJ's Days Sales Outstanding is ranked higher than
62% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.67 vs. JNJ: 62.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 62.81
Current: 62.81
53.94
62.81
Days Payable 91.99
JNJ's Days Payable is ranked higher than
63% of the 630 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.56 vs. JNJ: 91.99 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 91.99  Med: 111.33 Max: 147.94
Current: 91.99
91.99
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.49
JNJ's Dividend Yield % is ranked higher than
71% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. JNJ: 2.49 )
Ranked among companies with meaningful Dividend Yield % only.
JNJ' s Dividend Yield % Range Over the Past 10 Years
Min: 2.23  Med: 2.84 Max: 3.84
Current: 2.49
2.23
3.84
Dividend Payout Ratio 0.57
JNJ's Dividend Payout Ratio is ranked higher than
82% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. JNJ: 0.57 )
Ranked among companies with meaningful Dividend Payout Ratio only.
JNJ' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.51 Max: 0.65
Current: 0.57
0.39
0.65
3-Year Dividend Growth Rate 6.70
JNJ's 3-Year Dividend Growth Rate is ranked higher than
50% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. JNJ: 6.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
JNJ' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 6.7  Med: 13.4 Max: 17.2
Current: 6.7
6.7
17.2
Forward Dividend Yield % 2.52
JNJ's Forward Dividend Yield % is ranked higher than
68% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.77 vs. JNJ: 2.52 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.49
JNJ's 5-Year Yield-on-Cost % is ranked higher than
72% of the 874 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. JNJ: 3.49 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
JNJ' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.13  Med: 3.98 Max: 5.39
Current: 3.49
3.13
5.39
3-Year Average Share Buyback Ratio 1.20
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.00 vs. JNJ: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: 0.05 Max: 2.3
Current: 1.2
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.68
JNJ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. JNJ: 1.68 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JNJ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.84  Med: 1.61 Max: 3.6
Current: 1.68
0.84
3.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 31.93
JNJ's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
100% of the 85 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. JNJ: 31.93 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
JNJ' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.57  Med: 1.28 Max: 2.23
Current: 31.93
0.57
2.23
Price-to-Median-PS-Value 1.53
JNJ's Price-to-Median-PS-Value is ranked lower than
72% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. JNJ: 1.53 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JNJ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.02 Max: 1.88
Current: 1.53
0.49
1.88
Price-to-Peter-Lynch-Fair-Value 2.88
JNJ's Price-to-Peter-Lynch-Fair-Value is ranked lower than
78% of the 190 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. JNJ: 2.88 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
JNJ' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.53  Med: 1.75 Max: 4.26
Current: 2.88
0.53
4.26
Earnings Yield (Greenblatt) % 4.95
JNJ's Earnings Yield (Greenblatt) % is ranked higher than
65% of the 868 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.18 vs. JNJ: 4.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JNJ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.8  Med: 7.6 Max: 12.9
Current: 4.95
4.8
12.9
Forward Rate of Return (Yacktman) % 12.08
JNJ's Forward Rate of Return (Yacktman) % is ranked higher than
55% of the 411 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.51 vs. JNJ: 12.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JNJ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.7  Med: 13.2 Max: 17.1
Current: 12.08
1.7
17.1

More Statistics

Revenue (TTM) (Mil) $76,450.00
EPS (TTM) $ 0.39
Beta0.53
Short Percentage of Float0.66%
52-Week Range $117.00 - 148.32
Shares Outstanding (Mil)2,686.52

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 80,701 83,643 89,066
EBIT (Mil $) 23,908 25,605 25,054
EBITDA (Mil $) 30,974 33,725 35,141
EPS ($) 8.06 8.55 9.06
EPS without NRI ($) 8.06 8.55 9.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.52%
Dividends per Share ($) 3.58 3.68 3.89

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}